[Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women].
Data on efficacy and safety of angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension are reviewed. Such advantages of this preparation as 24-hour duration of action, lack of loss of hypotensive effect during long term administration, metabolic neutrality, and low rate of side effects are discussed. Antihypertensive action of moexipril is compared with other medicines. Special attention is devoted to various aspects of the use of moexipril in women in postmenopause, including positive effect on metabolism of bones and combination with hormonal replacement therapy.
Ostroumova
O D
OD
Paukov
S V
SV
Frolova
L I
LI
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017698:Postmenopause; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D003692:Delayed-Action Preparations; D044005:Tetrahydroisoquinolines; C058302:moexipril